Intelligence Feed event · Policy · 2026-10-07

    Oculis to present Licaminlimab at AAO ahead of PREDICT-1 trial readout around year-end

    Question

    Oculis to present Licaminlimab at AAO ahead of PREDICT-1 trial readout around year-end

    Direct answer

    Biopharmaceutical firm Oculis announced that Chief Executive Officer Riad Sherif will highlight clinical progress on Licaminlimab during Eyecelerator at AAO 2026 on October 8. The candidate is a novel topical anti-TNF alpha agent under evaluation for TNFR1-mediated dry eye disease. The pivotal PREDICT-1 registrational study is proceeding on schedule, with topline data expected before the end of the year.

    Original publisher
    Market Ontology
    Evidence through
    2026-10-07
    Published
    2026-10-20
    Revision
    1 · 2026-10-20

    Cite as: Market Ontology, “Oculis to present Licaminlimab at AAO ahead of PREDICT-1 trial readout around year-end”, revision 1, evidence through 2026-10-07. https://marketontology.com/market-events/2026-10-07/oculis-to-present-licaminlimab-at-aao-ahead-of-predict-1-trial-readout-around-ye-96cd89

    POLICY
    Oculis to present Licaminlimab at AAO ahead of PREDICT-1 trial readout around year-end
    Biopharmaceutical firm Oculis announced that Chief Executive Officer Riad Sherif will highlight clinical progress on Licaminlimab during Eyecelerator at AAO 2026 on October 8. The candidate is a novel topical anti-TNF alpha agent under evaluation for TNFR1-mediated dry eye disease. The pivotal PREDICT-1 registrational study is proceeding on schedule, with topline data expected before the end of the year.
    OCS
    Impact
    58
    OCT 7
    SIG
    85%
    OCS
    Oculis to present Licaminlimab at AAO ahead of PREDICT-1 trial readout around year-end
    Biopharmaceutical firm Oculis announced that Chief Executive Officer Riad Sherif will highlight clinical progress on Licaminlimab during Eyecelerator at AAO 2026 on October 8. The candidate is a novel topical anti-TNF alpha agent under evaluation for TNFR1-mediated dry eye disease. The pivotal PREDICT-1 registrational study is proceeding on schedule, with topline data expected before the end of the year.
    → Topline clinical trial readouts for registrational ophthalmic programs directly determine addressable commercial market size and biopharma equity valuation multiples ahead of FDA regulatory filing.
    Impact
    Biopharmaceutical firm Oculis announced that Chief Executive Officer Riad Sherif will highlight clinical progress on Licaminlimab during Eyecelerator at AAO 2026 on October 8. The candidate is a novel topical anti-TNF alpha agent under evaluation for TNFR1-mediated dry eye disease. The pivotal PREDICT-1 registrational study is proceeding on schedule, with topline data expected before the end of the year.
    Affected
    OCS
    Transmission
    Topline clinical trial readouts for registrational ophthalmic programs directly determine addressable commercial market size and biopharma equity valuation multiples ahead of FDA regulatory filing.

    How this development reaches the affected companies

    AssetExposure and channelDirectionEvidence
    OCSclinical pipeline binary trial outcome and regulatory submission pathWatch1-3mOculis confirmed PREDICT-1 trial topline data readout is on track for year-end 2026.

    Does this development affect your holdings?

    Enter your holdings to check them against this and other recent developments, review the decision that matters most, then set a monitor.

    Check this development against my holdings

    Review your initial audit before choosing ongoing portfolio scanning at $79/month.

    What happened next

    Price follow-up pending — no stored daily closes for these assets yet.

    Closing prices from stored daily bars; returns measured from the last close on or before the event date. Not a recommendation.

    No verifiable public source recorded for this card.

    Related

    Check this development against my holdings

    See today's live cards

    Public pages are published 24 hours after the product shows them. Desk shows every catalyst, event and causal reading as it happens, mapped to your holdings.

    Open Desk — $399/month